Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter observational study of target vancomycin concentrations in Chinese patients
ChiCTR-OPC-17012567Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vancomycin in Gram-positive bacterial infection, Staphylococcus aureus infection, bloodstream infection (BSI) and 7 more, sponsored by Huashan Hospital. Primary endpoint: Efficacy and safety. Started Apr 2017; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Gram-positive bacterial infectionStaphylococcus aureus infectionbloodstream infection (BSI)pneumoniaIntra-abdominal infection (IAI)
Beyond the preview
Go deeper on ChiCTR-OPC-17012567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012567.